WeVote
Log In

Bill

Bill

HD 1003

An Act to amend the General Laws, in relation to promoting the health and well-being of the residents of the Commonwealth of Massachusetts by establishing a comprehensive framework supporting public health and safety through regulated adult use, support services, and cultivation of psilocybin-containing fungi; and providing for taxation and appropriation thereof

194th Legislature (2025-2026) Introduced by Patrick Kearney

Massachusetts bill legalizes regulated psilocybin cultivation and adult sales, creating tax revenue and legal market while conflicting with federal Schedule I prohibition.

0
WeVote Research Nonpartisan
Bill Summary · HD 1003

Legislative bill overview

HD 1003 proposes to legalize and establish a regulated framework for adult use of psilocybin-containing fungi (magic mushrooms) in Massachusetts. The bill creates a licensing and taxation system for psilocybin cultivation and sales, alongside support services, similar to existing cannabis regulations in the state.

Why is this important

This legislation would make Massachusetts one of the first states to formally legalize psilocybin at the state level, representing a significant shift in drug policy. The bill could generate tax revenue, create a legal market that displaces illegal suppliers, and potentially enable therapeutic research and access in a regulated environment.

Potential points of contention

  • Medical vs. recreational use: The bill frames psilocybin as a health measure but legalizes "adult use," raising questions about whether recreational legalization is appropriate or if medical-only frameworks are more defensible
  • Federal legal conflict: Psilocybin remains a Schedule I controlled substance under federal law, creating potential conflicts with federal enforcement and interstate commerce complications
  • Public health concerns: Opponents may cite risks including psychological distress, potential for problematic use patterns, and effects on developing brains, particularly in younger adults
  • Precedent and timing: This could be seen as premature without more clinical evidence, or conversely, as overdue given emerging therapeutic research on psilocybin-assisted therapy

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.